Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston (G.T., R.G.), and Department of Pediatrics, Baylor College of Medicine (C.C., P.M., B.M.), Houston, Texas.
Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston (G.T., R.G.), and Department of Pediatrics, Baylor College of Medicine (C.C., P.M., B.M.), Houston, Texas
Drug Metab Dispos. 2018 Apr;46(4):397-404. doi: 10.1124/dmd.117.079160. Epub 2018 Feb 12.
Cytochrome P450 CYP3A4 is the most abundant drug-metabolizing enzyme and is responsible for the metabolism of ∼50% of clinically available drugs. Induction of CYP3A4 impacts the disposition of its substrates and leads to harmful clinical consequences, such as failure of therapy. To prevent such undesirable consequences, the molecular mechanisms of regulation of CYP3A4 need to be fully understood. induction is regulated primarily by the xenobiotic nuclear receptor pregnane-X receptor (PXR). After ligand binding, PXR is translocated to the nucleus, where it binds to the promoter and induces its gene expression. PXR function is modulated by phosphorylation(s) by multiple kinases. In this study, we determined the role of the c-Jun N-terminal kinase (JNK) in PXR-mediated induction of CYP3A4 enzyme in vitro. Human liver carcinoma cells (HepG2) were transfected with CYP3A4 luciferase and PXR plasmids, followed by treatment with JNK inhibitor (SP600125; SP) and PXR activators rifampicin (RIF) or hyperforin. Our results indicate that SP treatment significantly attenuated PXR-mediated induction of reporter activity, as well as gene expression and enzyme activity. JNK knockdown by siRNA (targeting both JNK 1 and 2) also attenuated CYP3A4 induction by RIF. Interestingly, SP treatment attenuated JNK activation by RIF. Furthermore, treatment with RIF increased PXR nuclear levels and binding to the promoter; SP attenuated these effects. This study shows that JNK is a novel mechanistic regulator of CYP3A4 induction by PXR.
细胞色素 P450 CYP3A4 是最丰富的药物代谢酶,负责代谢约 50%的临床可用药物。CYP3A4 的诱导会影响其底物的处置,并导致有害的临床后果,如治疗失败。为了防止这种不良后果,需要充分了解 CYP3A4 调节的分子机制。诱导主要受外源性核受体孕烷 X 受体 (PXR) 调节。配体结合后,PXR 易位到细胞核,在细胞核中与启动子结合并诱导其基因表达。PXR 的功能受多种激酶的磷酸化调节。在这项研究中,我们确定了 c-Jun N 端激酶 (JNK) 在体外 PXR 介导的 CYP3A4 酶诱导中的作用。用人肝癌细胞 (HepG2) 转染 CYP3A4 荧光素酶和 PXR 质粒,然后用 JNK 抑制剂 (SP600125;SP) 和 PXR 激活剂利福平 (RIF) 或贯叶连翘素处理。我们的结果表明,SP 处理显著减弱了 PXR 介导的报告基因活性、基因表达和酶活性的诱导。siRNA 敲低 JNK (针对 JNK1 和 JNK2) 也减弱了 RIF 诱导的 CYP3A4 诱导。有趣的是,SP 处理减弱了 RIF 诱导的 JNK 激活。此外,RIF 处理增加了 PXR 的核水平和与启动子的结合;SP 减弱了这些作用。这项研究表明,JNK 是 PXR 诱导 CYP3A4 诱导的新型机制调节剂。